KRAS and adrenal cortex carcinoma: To evaluate the prognostic value of the gene expression signature in combination with other clinical variables, including patient age at diagnosis, disease stage by AJCC criteria, smoking status, sex, and mutation status of certain oncogenes and tumor suppressor genes (i.e., KRAS, EGFR, and TP53), univariate and multivariate Cox proportional hazards regression analyses were performed in the ACC cohort.